Aviadenovirus
AssigneeAkzo Nobel N.V.
InventorsGuntram Paul, Michael Bernhard Hess
Life of this patent
Estimating the term…
Abstract
The invention relates to a new aviadenovirus which was isolated from a pigeon. The aviadenovirus according to the present invention comprises group-I specific antigen and cannot be neutralized by antiserum against any of the FAV serotypes 1-12. The present invention also relates to an antibody or antiserum immunoreactive with a fibre of the new aviadenovirus, a fibre thereof as well as a vaccin against PiAV related diseases comprising a chemically or physically inactivated virus an attenuated virus, a fibre or fragment thereof, a host cell transformed with a nucleic acid sequence encoding an amino acid sequence comprising an immunogenic determent or a functional variant thereof of a fibre of the aviadenovirus according to the present invention, together with a pharmaceutical carrier.
Claims5
An isolated and purified pigeon adenovirus (PiAV) comprising group I—specific antigen, which is not neutralized by antiserum against any of fowl adenovirus serotypes 1-12, and which is immune reactive in a cross-neutralization teat with a titer ratio of less than 16 in both directions with a PiAV isolate deposited with the CNCM under accession number I-1988.
Dependencies are inferred from the claim text.